Citius Oncology, Inc. (CTOR)
| Market Cap | 63.54M -2.4% |
| Revenue (ttm) | 5.61M |
| Net Income | -42.51M |
| EPS | -0.50 |
| Shares Out | 88.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,273 |
| Open | 0.7580 |
| Previous Close | 0.7999 |
| Day's Range | 0.6950 - 0.7611 |
| 52-Week Range | 0.4912 - 6.1900 |
| Beta | 3.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About CTOR
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Full Company ProfileFinancial Performance
Financial StatementsNews
Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO
Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), highlighted Phase 1 clinical data presented May 30 at the American Society of Clinical Oncology Annual Meeting eva...
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-t...
Citius Oncology registers to sell 32.93M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 32.93M shares of common stock. The company is not selling any…
Citius Oncology Registration statement: Registration filing
Citius Oncology filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy...
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ® Citius Pharma raised $5 million in a registered direct offering; Citius Oncology secured up to $36.5 mill...
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $36.5 million in debt and equity capital secured Broad payer coverage established with no reimburseme...
Citius Oncology Quarterly report: Q2 2026
Citius Oncology has published its Q2 2026 quarterly earnings report on May 15, 2026.
Citius Oncology Earnings release: Q2 2026
Citius Oncology released its Q2 2026 earnings on May 15, 2026, summarizing the period's financial results.
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 million tranche funded at closing; additional tranches subject to certain conditions Gross proceeds of ...
Citius Oncology announces initial shipment of LYMPHIR to Europe
Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, (CTXR), announced the initial shipment of LYMPHIR to Europe through one of its regional distribution partners, marking an...
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distribution by regional partners through Named Patient Programs in specific international markets CRANFO...
Citius Oncology provides commercial update on lymphir launch
Citius Oncology (CTOR)provided a commercial update on the U.S. launch of lymphir for the treatment of cutaneous T-cell lymphoma, highlighting continued adoption across leading oncology centers, broad ...
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integration CRANFORD, N.J., March 31, 2026 /PRNewswire/ -- Citius Oncology, ...
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings available CRANFORD, N.J., March 24, 2026 /PRNewswire/ -- Citius On...
Citius Oncology’s Lymphir shows positive results in gynecologic cancers
Citius Oncology (CTOR)announced positive topline results from a completed investigator-initiated Phase1 clinical trial evaluating the direct T-regulatory, or Treg, cell depletion activity of lymphir –...
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data of University of Pittsburgh-led t...
Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR
Citius Oncology (CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals (CTXR) announced positive topline safety and efficacy results from an inve...
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response ...
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
Revenue of $3.9M during the quarter ended December 31, 2025 reflects sales related to the launch of Lymphir. Cash and cash equivalents totaled $7.3M as of December 31, 2025 .
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
Q1 consolidated revenue was $3.9M, reflecting initial U.S. sales of Lymphir at Citius Oncology (CTOR). Cash and cash equivalents totaled $7.7M as of December 31, 2025.
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Onco...
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Phar...
Citius Oncology Quarterly report: Q1 2026
Citius Oncology has published its Q1 2026 quarterly earnings report on February 13, 2026.
Citius Oncology Earnings release: Q1 2026
Citius Oncology released its Q1 2026 earnings on February 13, 2026, summarizing the period's financial results.